Literature DB >> 7726522

Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

R A Zabinski1, K J Walker, A J Larsson, J A Moody, G W Kaatz, J C Rotschafer.   

Abstract

A previously established in vitro pharmacodynamic system was used to evaluate the antistaphylococcal activities of five fluoroquinolones under both aerobic and anaerobic conditions. Staphylococcus aureus ATCC 29213 was exposed to a 5-micrograms/ml concentration of each of the following fluoroquinolones: ciprofloxacin, ofloxacin, temafloxacin, sparfloxacin, and clinafloxacin. Terminal elimination half-lives of 4, 6, 8, 8, and 13 h were simulated for the respective drugs. Each fluoroquinolone was bactericidal under both aerobic and anaerobic conditions. However, the bactericidal activity of each fluoroquinolone was delayed by anaerobiosis. This difference in fluoroquinolone activity under aerobic and anaerobic conditions could not be attributed to any particular parameter or physiochemical property but was most likely caused by a combination of factors (e.g., variations in hydrophobicity, intracellular pH, antibiotic concentration, and structure-activity relationships). Fluoroquinolone uptake studies were also performed to investigate the possibility of active, energy-dependent transport mechanisms in S. aureus ATCC 29213. Uptake studies indicated that active efflux does occur in S. aureus ATCC 29213.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726522      PMCID: PMC162568          DOI: 10.1128/AAC.39.2.507

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

2.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

3.  Nalidixic acid: an antibacterial paradox.

Authors:  G C Crumplin; J T Smith
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

4.  The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo.

Authors:  P B Fernandes; C W Hanson; J M Stamm; C Vojtko; N L Shipkowitz; E St Martin
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

Review 5.  In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.

Authors:  F H Kayser; J Novak
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Routes of quinolone permeation in Escherichia coli.

Authors:  J S Chapman; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

7.  Mechanisms of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

8.  Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.

Authors:  R A Zabinski; K Vance-Bryan; A J Krinke; K J Walker; J A Moody; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

10.  Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model.

Authors:  M W Garrison; K Vance-Bryan; T A Larson; J P Toscano; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more
  8 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Authors:  David H Wright; Brent W Gunderson; Laurie B Hovde; Gigi H Ross; Khalid H Ibrahim; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 3.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

4.  Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.

Authors:  F J Boswell; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.

Authors:  S L Pendland; M Diaz-Linares; K W Garey; J G Woodward; S Ryu; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 6.  Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs.

Authors:  David A Sanchez; Luis R Martinez
Journal:  Crit Rev Microbiol       Date:  2018-12-06       Impact factor: 7.624

7.  MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; S H Zinner; G Cornaglia; Y A Portnoy
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.

Authors:  E Cormet-Boyaka; J F Huneau; A Mordrelle; P N Boyaka; C Carbon; E Rubinstein; D Tomé
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.